Source: EURLEX
Language: en
Format: md

|  |  |  |  |
| --- | --- | --- | --- |
| 19.9.2022 | EN | Official Journal of the European Union | C 359/22 |

---

Request for a preliminary ruling from the College van Beroep voor het bedrijfsleven (Netherlands) lodged on 11 May 2022 — Pesticide Action Network Europe (PAN Europe) v College voor de toelating van gewasbeschermingsmiddelen en biociden in the presence of: BASF Nederland BV (BASF)

(Case C-310/22)

(2022/C 359/23)

Language of the case: Dutch

Referring court

College van Beroep voor het bedrijfsleven

Parties to the main proceedings

Applicant: Pesticide Action Network Europe (PAN Europe)

Defendant: College voor de toelating van gewasbeschermingsmiddelen en biociden

In the presence of: BASF Nederland BV (BASF)

Questions referred

|  |  |
| --- | --- |
| 1. | Does it follow from the second paragraph of Article 4(1) of Regulation 1107/2009, [(1)](#ntr1-C_2022359EN.01002201-E0001) in conjunction with paragraph 3.6.5 of Annex II thereto, that the potential endocrine disrupting properties of an active substance need no longer be assessed during the assessment at national level of an application for authorisation of a plant protection product? |

|  |  |
| --- | --- |
| 2. | If the answer to the first question is in the affirmative, does it mean that the scientific insights and technical knowledge relating to endocrine disrupting properties, which, for example, underpin Regulations 283/2013 [(2)](#ntr2-C_2022359EN.01002201-E0002) and 2018/605, [(3)](#ntr3-C_2022359EN.01002201-E0003) need not be taken into account when assessing the authorisation of a plant protection product? How does that relate to the requirement of Article 29(1)(e) of Regulation 1107/2009 that such an assessment must be conducted on the basis of current scientific and technical knowledge? |

|  |  |
| --- | --- |
| 3. | If the answer to the first question is in the affirmative, how can a non-governmental organisation such as the appellant be said to have an effective remedy under Article 47 of the Charter to refer the approval of an active substance to a court of law? |

|  |  |
| --- | --- |
| 4. | If the answer to the first question is in the negative, does it mean that, when assessing an application for authorisation, the state of scientific and technical knowledge about that endocrine disrupting property at that time is decisive? |

---

---

[Top](#document1)